Cellectar Biosciences, INC 8-K filings

Cellectar Biosciences reported Q2 2026 results, highlighting progress in its iopofosine I 131 and CLR 125 trials, initiation of Phase 3 site activation, and a significant capital raise.

Cellectar Biosciences stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the share reserve by 2 million shares and ratifying the appointment of Deloitte & Touche LLP.

Cellectar Biosciences announces the departure of Dr. Stefan D. Loren from its Board of Directors and the appointment of Andrew Gu, nominated by Nantahala Capital Management, LLC.

Cellectar Biosciences announced positive Q1 2026 financial results, positive follow-on data for iopofosine I 131, and secured up to $140 million in financing.

Cellectar Biosciences announced a registered direct offering and concurrent private placement raising approximately $35 million to fund its Phase 3 trial for iopofosine I 131.

Cellectar Biosciences announced its 2025 financial results, showcasing significant pipeline advancements and a reduced net loss, while addressing future funding needs.

Cellectar Biosciences reports Q3 2025 financial results, advances regulatory strategy for iopofosine I-131 in Europe, and progresses its radioconjugate pipeline.

Cellectar Biosciences, Inc. announced the exercise of existing warrants generating $5.8 million in gross proceeds and extending its cash runway into Q3 2026.

Cellectar Biosciences announced the EMA's Scientific Advice Working Party advised that filing for Conditional Marketing Authorization for iopofosine I 131 in Waldenstrom macroglobulinemia could be acceptable.

Cellectar Biosciences reports Q2 2025 results, plans FDA accelerated approval for iopofosine I 131 in Waldenstrom Macroglobulinemia, and secures new funding.

Cellectar Biosciences announced positive clinical data for its lead drug candidate, iopofosine, in multiple cancer types, alongside plans to advance two new radiopharmaceutical candidates, CLR 125 and CLR 225, into Phase 1 studies, contingent on securing additional financing.

Cellectar Biosciences, Inc. has effected a one-for-thirty reverse stock split of its common stock, effective June 24, 2025, to consolidate shares and adjust its per-share price.

Cellectar Biosciences, Inc. announced a one-for-thirty reverse stock split of its common stock, effective June 24, 2025, significantly reducing outstanding shares.

Cellectar Biosciences, Inc. announced that its stockholders approved a reverse stock split, the election of two Class II directors, the ratification of its independent auditor, and executive compensation at its 2025 Annual Meeting.

Cellectar Biosciences, Inc. announced it will raise approximately $2.5 million through an inducement offer for the immediate exercise of existing warrants at a reduced price.

Cellectar Biosciences reported its Q1 2025 financial results, announced a strategic review process, and is seeking conditional approval from the EMA for Iopofosine I 131 in Waldenstrom Macroglobulinemia.

Cellectar Biosciences announces it is exploring strategic alternatives, including potential mergers, acquisitions, or partnerships, to maximize stockholder value and has engaged Oppenheimer & Co. Inc. as its exclusive financial advisor.

Cellectar Biosciences modifies executive severance agreements and updates its bylaws to align with Delaware law and revise stockholder meeting procedures.

Cellectar Biosciences reports its 2024 financial results, highlights regulatory progress for its lead drug candidate, iopofosine I 131, and outlines plans for upcoming clinical trials.

Cellectar Biosciences received a notice from Nasdaq on January 30, 2025, indicating that its common stock does not meet the minimum bid price requirement for continued listing.

Cellectar Biosciences plans to highlight its 2025 strategic initiatives, including advancing iopofosine I 131 and radiotherapeutic assets, at the Biotech Showcase during the JP Morgan Healthcare Conference.

Cellectar Biosciences is restructuring its operations, including a 60% workforce reduction, to focus on new therapeutic programs after receiving feedback from the FDA regarding its lead drug candidate, iopofosine I 131.

Cellectar Biosciences reported positive results from its Phase 2 CLOVER-WaM study and raised $19.4 million, with potential for an additional $73.3 million.

Cellectar Biosciences files a revised auditor consent to correct an omission in a previous filing, with no impact on previously reported financials.

Cellectar Biosciences has regained compliance with Nasdaq listing rules after filing restated financial statements and a quarterly report.

Cellectar Biosciences received a delisting notice from Nasdaq due to a delay in filing its quarterly report, stemming from the need to restate prior financial statements.

Cellectar Biosciences reported strong Q2 2024 financial results and positive clinical trial data for iopofosine I 131, with plans to file an NDA in Q4 2024.

Cellectar Biosciences has determined that its previously issued financial statements for multiple periods should no longer be relied upon due to accounting errors related to warrants issued in 2022, necessitating a restatement and delaying its upcoming quarterly report.

Cellectar Biosciences announced positive results from its CLOVER WaM pivotal study, with iopofosine I 131 demonstrating an 80% overall response rate and a 56.4% major response rate in relapsed/refractory Waldenstrom's macroglobulinemia patients, exceeding the primary endpoint.

Cellectar Biosciences has received approximately $19.4 million in gross proceeds from the exercise of Tranche B warrants and the sale of new warrants, with the potential to raise an additional $73.3 million.